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ABSTRACT 24 
The human gut microbiota comprises approximately 100 trillion microbial cells and has a significant 25 
effect on many aspects of human physiology including metabolism, nutrient absorption and immune 26 
function. Disruption of this population has been implicated in many conditions and diseases, including 27 
examples such as obesity, inflammatory bowel disease and colorectal cancer that are highlighted in 28 
this review. A logical extension of these observations suggests that the manipulation of the gut 29 
microbiota can be employed to prevent or treat these conditions. Thus, here we highlight a variety of 30 
options, including the use of changes in diet (including the use of prebiotics), antimicrobial-based 31 
intervention, probiotics and faecal microbiota transplantation, and discuss their relative merits with 32 
respect to modulating the intestinal community in a beneficial way. 33 
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INTRODUCTION 37 
Humans are now thought of as “superorganisms” on the basis of the genetic potential encoded within 38 
our resident microbial populations in addition to our own genome. It has been suggested that our 39 
microbiota develops with us and alters its own composition and gene expression in response to 40 
changing environmental conditions [1]. The largest and most varied of the human-associated 41 
microbial communities exists in the gastrointestinal (GI) tract. 42 
The gut microbial population is made up of approximately 1000 species from relatively few 43 
phyla. The most abundant species are members of the phyla Firmicutes and Bacteroidetes, with 44 
smaller numbers being representatives of the Proteobacteria, Fusobacteria, Cyanobacteria, 45 
Verrucomicrobia and Actinobacteria, amongst others [2]. The gut microbiota is composed mainly of 46 
anaerobes, which outnumber facultative anaerobes and aerobic bacteria by approximately 2-3 orders 47 
of magnitude [3]. It has been noted that, although there is great inter-individual variation in the 48 
composition of the gut microbiota, there are a conserved set of encoded functions shared between 49 
individuals referred to as the core gut microbiome [4], suggesting that it is the functionality of the 50 
microbiota rather than its composition that is of greatest importance to the host. The functions and 51 
pathways encoded in the core microbiome are thought to confer the greatest benefit to the host and are 52 
probably essential for the correct functioning of the gut.  Some well-studied benefits include 53 
protection against potential pathogens, digestion of polysaccharides, production of essential vitamins, 54 
stimulation of angiogenesis, regulation of fat storage and modulation of the host’s immune system [5]. 55 
Recent studies have also shown that the gut microbiota influences the gut-brain axis and shapes stress-56 
related symptoms such as anxiety and pain tolerance [6]. 57 
Advances in high throughput sequencing technologies (HTS) and tools enabling comparative 58 
analysis of the large amount of data that are generated by these technologies have led to a better 59 
understanding of what constitutes a ‘healthy” gut microbiota. One of the most interesting observations 60 
drawn from the data generated is that the resident microbiota encodes > 100 fold more genes than the 61 
human genome [7]. The genes present in the microbiome are responsible for many functions essential 62 
to host survival but which are not encoded within the human genome. Due to the range and 63 
importance of the metabolic and biochemical processes carried out by the microbiome it has been 64 
referred to as “our hidden organ” [8].  65 
While the “healthy” gut microbiota is seen to be a stable community, there are stages within 66 
the life cycle of humans during which there can be dramatic alterations in the structure and function of 67 
this population. These “natural” changes begin with initial colonisation immediately following birth 68 
and subsequent development of the microbiota over the first two years of life. The earliest colonizers 69 
are usually members of the enterococci and enterobacteria followed by strict anaerobes such as 70 
Bifidobacterium, Clostridium and Bacteroides spp. once the initial oxygen supply present has been 71 
depleted [9]. Despite this general pattern, it is important to appreciate that the method of delivery and 72 
subsequent feeding type have a profound effect on the initial populations [10]. Once the infant reaches 73 
two years of age the microbiota has already begun to transform into its adult form, which is thought to 74 
be relatively stable before it undergoes a final “shift” when entering old age [11]. Indeed, with respect 75 
to the latter phenomenon, a study by Claesson and colleagues that compared the gut microbiota of 76 
individuals ages 65 or older to 9 younger control subjects has highlighted significant changes in 77 
community structure associated with ageing, specifically an increase in the abundance of Bacteroides 78 
spp. and distinct shifts within the Clostridium genus [12]. It has been hypothesised that alterations in 79 
the elderly microbiota are due to physiological changes in the elderly gastrointestinal tract such as 80 
chronic low-grade inflammation, in addition to dietary habits [13]. 81 
It has been well established that the human gut microbiota is integral to human health, and, as 82 
will be discussed below, it also plays an important role in gastrointestinal disease. It is therefore 83 
reasonable to assume that modulation of the gut microbiota can be used as a therapeutic approach to 84 
treating chronic gastrointestinal diseases. Thus, this review is focussed primarily on the methods that 85 
can be employed to modulate the gut microbiota while highlighting the benefit of guiding community 86 
structure towards a more desirable state. 87 
 88 
ROLE OF THE GUT MICROBIOTA IN GASTROINTESTINAL DISEASE 89 
There are a growing number of gastrointestinal conditions that have been linked with alterations in the 90 
gut microbiota. To properly implement strategies to modulate the gut microbiota as a therapeutic tool, 91 
it is first necessary to understand the role of the gut microbiome in specific GI, and other, diseases.  92 
Given the recent rapid expansion in the number of disease states that have been linked with alterations 93 
in the gut microbiota, it is not possible to address the issue in depth in the confines of this review. 94 
Instead, some well-studied examples are discussed below and we refer you to some other recent 95 
reviews that address this topic in depth [3,14].  96 
Inflammatory Bowel Disease 97 
Inflammatory Bowel Disease (IBD) is a relapsing disorder characterized by chronic 98 
inflammation of the GI tract, and of the colon in particular. The two major types of IBD are Crohn’s 99 
disease (CD) and ulcerative colitis (UC).  Evidence suggests that IBD is a complex disease arising 100 
from a combination of genetic and environmental factors. From a genetics perspective, genome-wide 101 
association studies (GWAS) and subsequent meta-analyses have identified a total of 163 genetic risk 102 
loci for IBD [15-17]. A German twin cohort study confirmed the strong genetic element to IBD by 103 
observing that monozygotic twins are significantly more likely to be concordant for the disease than 104 
dizygotic twins [18]. However, concordance rates between monozygotic twins are nonetheless low 105 
(35% for CD and 16% for UC), highlight that environmental triggers do indeed play an important role 106 
in both diseases, and in UC in particular. 107 
It is notable that murine studies have revealed that the presence of commensal enteric bacteria 108 
is necessary for the development of spontaneous colitis and immune system activation [19] and, 109 
indeed, transferring colitogenic gut microbiota into healthy mice can induce spontaneous colitis [20]. 110 
Similarly, it has consistently been observed that patients suffering from IBD harbour an altered gut 111 
microbiota [21,22], specifically reduced bacterial diversity and changes within the Firmicutes phylum 112 
[23]. The changes in microbiota composition appear to be somewhat different between UC and CD. 113 
For example, decreased abundance of the butyrate-producing bacteria Roseburia hominis and 114 
Faecalibacterium prausnitzii have been observed in UC patients relative to controls [24], while the 115 
opposite has been observed in CD patients who possessed increased F. prausnitzii levels in addition to 116 
a reduced overall diversity [25]. Although these microbial changes could be a result of increased 117 
inflammation, evidence suggests that it is more likely that shifts in the microbiota are involved in the 118 
disease’s pathogenesis, either due to an intolerance to a specific group of commensals or due to an 119 
imbalance between protective and harmful members of the population [21,23,26].  120 
Irritable Bowel Syndrome 121 
Irritable Bowel Syndrome (IBS) is a chronic GI disorder that presents with symptoms 122 
including abdominal pain, bloating and altered bowel function. IBS is divided into several subtypes 123 
based on stool characteristics; diarrhoea, constipated or mixed. It’s cause, as of yet, is not fully known 124 
and although the aetiology is thought to be a combination of a number of factors, it is hypothesised 125 
that perturbations in the normal microbial microbiota play a role in the syndrome’s characteristic low-126 
grade inflammation [27]. Indeed, Rajiić-Stojanović et al. used qPCR and phylogenetic microarrays to 127 
show that the gut microbiota of IBS patients differed significantly from healthy controls, with IBS 128 
sufferers having a 2-fold higher Firmicutes to Bacteroidetes ratio and correlation analysis implicating 129 
several groups of Firmicutes and Proteobacteria in IBS pathogenesis [28]. Contrastingly, Jalanka-130 
Tuovinen and colleagues observed that the faeces of diarrhoea-predominant IBS sufferers harboured 131 
12-fold higher levels of several Bacteroidetes members. This group also noted that healthy controls 132 
have 35-hold higher numbers of uncultured clostridia [29]. Interestingly, these alterations in the 133 
microbiota correlated with changed in expression of host genes involved in amino acid synthesis, cell 134 
junction integrity and inﬂammatory response, suggesting impaired epithelial barrier function in IBS 135 
patients. Small intestinal bacterial overgrowth (SIBO), which is characterized by excessive bacteria in 136 
the small intestine, has also been put forward as a possible factor in IBS aetiology [30]. Bacterial 137 
overgrowth can result in overproduction of gas in the small intestine by degradation of carbohydrates, 138 
contributing to the symptoms of IBS [31]. The most commonly isolated bacteria from SIBO patients 139 
are Escherichia coli, Streptococcus, Lactobacillus, Bacteroides and Enterococcus species [32]. 140 
However it is not fully understood if any of these microorganisms play a specific role in IBS 141 
progression. It should also be recognised that differences between studies may be due to the causative 142 
microorganisms or imbalances differing between IBS subtypes. Regardless, a bacterial role in IBS 143 
onset would seem to be clear, as further evidenced by the disease’s response to antibiotic therapy [33] 144 
and differential expression levels of Toll-like receptors in colonic biopsies of patients with IBS [34].  145 
 146 
Obesity 147 
Obesity is a complex disease resulting from a prolonged imbalance of energy input and energy 148 
expenditure. Modern dietary and exercise habits are major contributing factors but it is now 149 
understood that the composition and function of the gut microbiome plays an important role through a 150 
variety of mechanisms [35]. A number of comprehensive reviews focussing on the association 151 
between the microbiota and obesity have been published [36,37]. Differences in the gut microbiota 152 
between obese and lean individuals have been the subject of great scrutiny. A range of different 153 
murine models have been used to this end, including genetically obese [38,39], diet-induced obese 154 
[40] and humanized [41] mice. Although a number of studies have reported an increased ratio of 155 
Firmicutes to Bacteroidetes in obese mice compared to their lean counterparts, these findings continue 156 
to be the subject of much debate in relation to human studies, which have revealed a number of 157 
microbial populations that have been associated with obesity [37]. Notably, transplanting the faecal 158 
microbiota of obese humans into germ-free mice brought about significant increases in the fat-mass 159 
of, and obesity-related metabolic phenotypes in, these mice relative to those which occurred when the 160 
corresponding faecal microbiota from lean monozygotic twins was transplanted [42]. Furthermore, a 161 
second trial showed that cohousing mice harbouring these two microbial communities prevented 162 
development of the obese phenotype, a trend correlating with invasion of specific Bacteroidetes 163 
members from lean to obese microbiota [42]. Another recent paper of note has linked the mucin-164 
degrading bacterium Akkermansia muciniphila with obesity and type 2 diabetes [43]. The study 165 
showed A. muciniphila abundance was decreased in obese and type 2 diabetic mice and that prebiotic 166 
feeding normalised A. muciniphila levels, which in turn correlated with an improved metabolic 167 
profile. Orally administered A. muciniphila also reversed high-fat diet induced metabolic disorders in 168 
these mice [43]. The results of these, and other studies, make it apparent that the microbiota plays a 169 
role in obesity but the specific changes associated with the phenotype are complex and remain 170 
unclear. 171 
Type 2 Diabetes 172 
Type 2 diabetes (T2D) is a metabolic disorder with both genetic and environmental 173 
influences. It is a major health concern throughout the western world, arising particularly as a result of 174 
increasing obesity-related insulin resistance [44,45]. It is evident from a number of studies that the gut 175 
microbiome is altered in patients suffering from T2D [46-48], although, as with many obesity-related 176 
associations, it is not clear whether these changes are a cause or simply a consequence of the disorder. 177 
Nonetheless, it was an interesting development when, in 2010 it was reported that the proportions of 178 
Firmicutes, and in particular species of clostridia, were significantly reduced in T2D sufferers 179 
compared to healthy individuals [46]. A subsequent, and much larger, metagenome-wide association 180 
study of 345 Chinese individuals showed that the gut microbiota of patients with T2D was 181 
characterized by a moderate degree of microbial dysbiosis, lower levels of butyrate-producing 182 
bacteria and an enrichment of microbial functions relating to sulphate reduction and resistance to 183 
oxidative stress [48]. Almost all of the microbial genes enriched in T2D patients were from 184 
opportunistic pathogens, including genes from several Clostridium spp. as well as Bacteroides caccae 185 
[48]. These results provided a number of markers that were assessed to determine if they could 186 
successfully identify patients with T2D on the basis of an analysis of faecal samples. Notably, this 187 
method successfully identified the T2D disease state with 81% accuracy [48], i.e. a greater success 188 
rate than using a combination of clinical risk factors and genetic information [49]. 189 
Colorectal Cancer 190 
Colorectal cancer (CRC) is the third most common cause of cancer mortality in the world 191 
[50]. It is becoming apparent that, even though a single causative microorganism has not been 192 
explicitly identified, the gut microbiota plays a role in CRC [51,52]. Wang and colleagues noted that 193 
there was a clear segregation between the microbiota of CRC patients and healthy volunteers, 194 
particularly, as was the case for T2D, a decrease in the abundance of butyrate producers and an 195 
increase in the incidence of opportunistic pathogens in CRC patients [53]. Members of the 196 
Fusobacterium genus have also been recently identified as potential causative agents after it was 197 
observed that they were enriched in colorectal carcinomas [54], a pattern also noted in other studies 198 
[53,55-57]. The authors hypothesised that Fusobacterium spp. may contribute to tumourigenesis by an 199 
inflammatory-mediated mechanism, a hypothesis supported by a follow-up study which showed that 200 
members of fusobacteria could generate a proinflammatory microenvironment through the 201 
recruitment of tumour-infiltrating immune cells [58]. E. coli has also been linked with CRC in a 202 
number of studies. Arthur et al. observed that E. coli levels were ~100-fold higher in the microbiota 203 
of the colitis-susceptible IL10 
-/-
 mouse strain compared to the wild type [51]. They went on to show 204 
that E. coli NC101 mono-association significantly promoted development of invasive mucinous 205 
adenocarcinomas in azoxymethane treated, IL10 
-/-
 mice and that deletion of the polyketide synthase 206 
(pks) genotoxic island from this E. coli strain decreased tumour multiplicity and invasion [51]. While 207 
further investigations are required, these results suggest that colitis promotes tumourigenesis in mice 208 
by altering the composition of the gut microbiota and selecting for members with genotoxic 209 
capabilities. 210 
Ultimately, identification of microorganisms, microbial populations or microbial 211 
functionalities involved in GI disease is fundamental to developing novel therapies. It is evident that 212 
the gut microbiota plays a large role in intestinal health and disease, and therefore manipulation or 213 
modulation of this community, is a clinical option that merits serious consideration.  214 
 215 
MODULATION OF THE GUT MICROBIOTA 216 
Modulation by Diet 217 
Environmental factors, including dietary intake, can shape the composition of the intestinal 218 
microbial community.  Indeed, a number of recent studies have highlighted the links between diet and 219 
distinct microbial profiles and, in turn, overall gut health [40,59-63]. Having an understanding of how 220 
diet influences microbial communities will be of critical importance with respect to employing food to 221 
beneficially alter the gut microbiota.  222 
The amount, type and balance of the three main dietary components, i.e. protein, 223 
carbohydrates and fat, have a profound impact on the gut microbiota. Short-chain fatty acids (SCFAs), 224 
primarily butyrate, propionate and acetate, are the major end products from the microbial degradation 225 
of carbohydrates and protein in the gut. SCFAs have a diverse range of physiological effects on the 226 
host, with perhaps the most important being their oxidation by mucosal cells to provide energy. An 227 
excellent review of the benefits of SCFAs on the host has been published by Macfarlane & 228 
Macfarlane [64]. The majority of microbial protein degradation occurs in the distal colon where the 229 
pH is neutral and conditions are favourable for the growth of proteolytic bacteria such as Bacteroides 230 
spp., Propionibacterium spp. and Clostridium perfringens [65,66]. The main pathway of protein 231 
degradation by this population is deamination of amino acids to the aforementioned SCFAs and 232 
ammonia [67], high concentrations of the latter have been shown to act as tumour promoters in rats 233 
[68]. The range of end products generated by protein digestion is broader than that of carbohydrates 234 
(see below) and also includes branched-chain amino acids, phenols, indoles and amines [69]. The 235 
majority of studies examining the effect of dietary protein on the gut microbiota have focussed 236 
primarily on the detection of altered fermentation products in the cecum [70] and faeces [71]. 237 
However, the effects of whey protein isolate on the microbiota have been the topic of some scrutiny in 238 
recent years as it has been indicated that dairy products can alleviate several disorders relating to 239 
metabolic syndrome [72]. One such study noted significantly increased counts of bifidobacteria and 240 
lactobacilli in the faeces of rats whose diets included cheese whey protein isolate or casein 241 
supplemented with either threonine or cysteine [73]. Whey protein isolate (WPI) has also been 242 
observed to alter the composition of the gut microbiota of mice in a dose-dependent manner [74]. All 243 
mice whose high fat diet was supplemented with WPI had significantly increased proportions of 244 
Lactobacillaceae and significantly decreased proportions of Clostridiaceae compared to high-fat fed 245 
controls, and increasing the amount of total energy derived from WPI caused a more profound shift in 246 
the microbiota [74]. Certain components of the normal human dietary intake of carbohydrates cannot 247 
by digested directly by the host and act as the major diet-derived energy source for microorganisms in 248 
the gut [75]. This fraction, comprised largely of resistant starches and non-starch polysaccharides, is 249 
degraded by microbial fermentation to a mixture of gasses and the aforementioned SCFAs. Many 250 
such carbohydrates are also referred to as prebiotics. The term prebiotic was introduced by Gibson 251 
and Roberfroid in 1995 [76] and are defined as “selectively fermented ingredients that allow specific 252 
changes, both in the composition and/or activity in the gastrointestinal microflora that confer benefits 253 
upon host well-being and health” [77]. Prebiotics have most frequently been employed with a view to 254 
stimulating the growth of either lactobacilli or bifidobacteria, with many studies focussing on inulin 255 
[78-80], oligofructose [81,82] or fructooligosaccharides [83,84]. There is a substantial body of 256 
evidence linking prebiotic consumption to human health benefits through modulation of the gut 257 
microbiota, with research in this area having been the subject of  a number of recent reviews [85-87]. 258 
In one particularly notable recent study, it was observed that supplementing the murine diet with 259 
SCFAs or fructooligosaccharides caused a shift in microbiota composition which strongly correlated 260 
with beneficial changes in body weight, adiposity and glucose control. These physiological changes 261 
were brought about via butyrate- and propionate-mediated activation of intestinal gluconeogenesis 262 
[88]. 263 
The majority of dietary fat is absorbed in the human small intestine but it has been shown that 264 
a substantial amount survives digestion and can be recovered in faeces [89]. The undigested portion 265 
passes through the colon where it can have a profound effect on the intestinal microbiota. Murphy et 266 
al. observed that high-fat feeding caused a greater compositional change in the gut microbiota than 267 
genetically induced obesity [90], in accordance with a previous study which showed that, when fed a 268 
high-fat diet, RELMβ knockout mice showed a significantly altered gut community while staying 269 
lean. RELMβ knockout mice were employed as they are known to stay relatively lean when fed a 270 
high-fat diet. The authors could therefore conclude that the change in diet, as opposed to the obese 271 
state, was responsible for the observed changes in the microbiota [91]. Many studies have established 272 
that mice fed a high-fat diet have significantly dissimilar microbial populations in the gut compared to 273 
mice fed on normal chow [38,40,92]. However, a recently published study showed that life-long 274 
calorie restriction significantly altered the gut microbiota in mice fed on both high-fat and low-fat 275 
diets [93]. This implies that not only the fat content of the diet, but also the number of calories 276 
consumed, has the potential to influence the bacterial communities present in the GI tract. The study 277 
also linked changes in the gut microbiota to claims that calorie restriction promotes healthy-ageing 278 
and increases lifespan in various animal models as the healthiest and longest living mice were those 279 
that were fed a low fat diet with calorie restriction [93]. In addition to the studies referenced above, 280 
there are many excellent reviews of the effect of dietary fat on the intestinal microbiota [37,94,95]. 281 
This specific combination of dietary components can vary according to geographic location, 282 
food availability, cultural practices and age and can have a profound impact on the conditions within 283 
the gut and the requirements of the microbiota (Table 1 highlights some studies which have 284 
investigated this impact). In one instance, the faecal microbiota of European children and children 285 
from an African village in Burkina Faso, whose diets differed considerably, was investigated. The diet 286 
of the African children was predominately vegetarian; high in starch, fibre and plant polysaccharides 287 
and low in fat and animal protein. This diet correlated with a significant increase in the 288 
Bacteroidetes:Firmicutes ratio in addition to an abundance of Prevotella and Xylanibacter when 289 
compared to the microbiota of the children consuming a carbohydrate-rich European diet [96]. The 290 
Xylanibacter genus, which was absent in European children, is known to contain genes for xylan and 291 
cellulose hydrolysis and so it was hypothesised that the gut microbiota coevolved with the 292 
polysaccharide-rich diet of the Burkina Faso children, allowing them to increase the energy extracted 293 
from dietary fibre while also conferring protection from inflammation and non-infectious colonic 294 
disease [96]. The comparatively high abundance of Prevotella in the faecal microbiota of the African 295 
children and the fact that it coincides with a carbohydrate-rich diet is consistent with the observations 296 
of Wu et al. who found that the overall composition of the microbiota was strongly associated with 297 
long-term diet [62].  Specifically, a diet rich in protein and animal fat was associated with higher 298 
proportions of Bacteroides while Prevotella were more abundant when the diet was enriched with 299 
plant-derived carbohydrates [62]. A recent study by De Filippo et al. took these investigations a step 300 
further by focussing specifically on the effect of diets composed entirely of animal or plants products 301 
on the gut microbiota [61]. It revealed that an animal-based diet increased the numbers of bile-tolerant 302 
microorganisms present and decreased the numbers of plant polysaccharide degrading Firmicutes. 303 
Interestingly, the respective diets brought about a transcriptional response among the gut microbiota 304 
that was consistent with previously reported differences in gene abundances between herbivorous and 305 
carnivorous animals [61]. In other studies, members of the Clostridium clusters IV and XIVa have 306 
been found to be enriched in the faeces of omnivores compared to vegetarians and lacto-vegetarians, 307 
who generally consume higher proportions of carbohydrates as part of their diet [97-99]. These 308 
clusters of bacteria are noted for their ability to convert dietary fibre to SCFAs. 309 
The overall dietary patterns in the De Filippo study above are similar to a study in mice where  310 
conventionalised mice were switched from a low-fat diet rich in complex plant polysaccharides 311 
(CHO) to an obesity-inducing high-fat/simple carbohydrate “Western” diet [40].  Mice fed on the 312 
“Western” diet had a significantly lower level of bacterial diversity, a characteristic seen to be an 313 
indicator of an unhealthy microbiota [59]. These mice possessed a significantly higher relative 314 
proportion of Firmicutes and lower relative proportions of Bacteroidetes compared to littermates 315 
which remained on the CHO diet. This population shift is similar to what is seen in the ob/ob mouse 316 
model of obesity [38] but differs in that the Firmicutes shift in the genetically-induced obesity model 317 
is division-wide whereas the dietary intervention above caused a bloom in a single uncultured clade 318 
within the Mollicutes class. A subsequent microbiota transplantation from these diet-induced obese 319 
mice into germ-free recipients promoted greater adiposity than transplants from lean donor [38]. A 320 
further study by the same group showed that this response of the microbiome to dietary intervention is 321 
rapid and can occur within 24 hours [41], a phenomenon also observed by Wu et al., [62].  322 
 A gut microbiota with decreased diversity has been linked with increased frailty and poorer 323 
general health in elderly subjects [60]. In this study, clustering of subjects by diet, residence location 324 
and by microbial groupings was apparent. Ultimately, it was evident that subjects that were living in 325 
the community had a healthier and more varied diet than subjects in long-term residential care, which 326 
gave rise to a more diverse gut microbiota with significant changes being noted at phylum and family 327 
levels. Differences were also apparent at the genus level with long-stay subjects possessing higher 328 
levels of Parabacteroides, Eubacterium, Anaerotructus, Lactonifactor and Coprobacillus, while 329 
Coprococcus and Roseburia (both members of the Lachnospiraceae family) were more abundant in 330 
community-dwelling subjects [60]. The data also linked microbiota composition to the duration spent 331 
in long-stay care. The longer the subject stayed in residential care (and consumed a less varied diet), 332 
the more dissimilar their microbiota became to the microbiota of healthy community-dwelling 333 
subjects [60]. Another study investigating the temporal relationship between food intake, gut 334 
microbiota and metabolic and inflammatory phenotypes reported that individuals with reduced 335 
microbial gene richness present more pronounced dys-metabolism and low-grade inflammation than 336 
their richer counterparts [100]. This microbiota-associated phenotype was suggested to be a result of 337 
long-term dietary habits as it was noted that these subjects seemed to consume less fruits, vegetables 338 
and fish than their high gene richness equivalents, i.e. a pattern consistent with that reported by 339 
Claesson et al [60]. More specifically, the initial sampling of the cohort (49 obese or overweight 340 
subjects) showed that subjects with lower gene richness in the gut microbiota presented with 341 
increased obesity-associated phenotypes such as higher insulin resistance and increased levels of 342 
fasting serum triglyceride, LDL cholesterol and inflammation. Dietary intervention (6 week energy-343 
restricted high-protein diet) increased gene richness significantly in individuals that originally had a 344 
low gene count. This increased gene richness remained after the subjects were switched to a 6 week 345 
weight-maintenance diet suggesting that dietary intervention as the potential to, at least partially, 346 
correct a loss of richness in the microbiota [100]. 347 
Given the complexity of the relationship between diet and the gut microbiota, there would 348 
seem to be merit in developing and utilising models that allow one to elucidate the specific 349 
relationship between specific dietary components and microorganisms. An elegant strategy to 350 
facilitate this was provided by Faith et al. when they introduced a model community of ten human gut 351 
bacteria into gnotobiotic mice and developed a relatively simple statistical model which predicted 352 
over 60% of the species variations that occurred in response to changes in diet [101]. The amount of 353 
casein in the diet was observed to be significantly associated with the abundances of all 10 microbial 354 
species and highly correlated with the total biomass of the community. Interestingly, E. coli and 355 
Clostridium symbosium were the only two species that had a second dietary variable significantly 356 
associated with their abundance, sucrose and starch respectively. The statistical model was 357 
subsequently able to determine 61% of the variation of the community members when the host was 358 
fed a new, previously unseen diet [101]. These results represent a significant step towards tailoring 359 
diet to address chronic microbiota-associated illnesses and a potential evolution of research within the 360 
field. 361 
It is clear that microbial composition varies between groups living on different long-term 362 
diets. Recent investigations that suggest that short-term dietary changes can also alter the 363 
composition, and result in changes to the metabolic activity of the microbiome as a whole, are 364 
noteworthy but further investigations are required to determine how best to take advantage of these 365 
observations. 366 
Modulation by Antimicrobials 367 
The manipulation of the gut microbiota by antimicrobials is emerging as an attractive 368 
therapeutic strategy (Table 2). The success of this approach is likely to ultimately depend on the target 369 
specificity of the antimicrobials in question, especially as the undesirable consequences of the overuse 370 
of broad-spectrum antimicrobials have become ever more apparent in recent years. For quite some 371 
time broad-spectrum antibiotics have been commonly used by clinicians as they can be used in the 372 
treatment of a wide range of infections or when the causative bacterium has not been formally 373 
identified. However, due to the frequent use of these antibiotics, the spread of antibiotic resistance is 374 
now posing a serious problem in health care settings.  In addition, antibiotic therapies not only affect 375 
the target microorganism but can also perturb the host gut microbial communities. The extent of this 376 
damage has recently become more evident through the application of high throughput DNA-based 377 
sequencing technologies to assess the composition of gut microbial populations (for review see Cotter 378 
et al. 2012) [102]. Here we provide just a few examples of the negative consequences of the use of 379 
broad-spectrum antibiotics on the gut microbiota and, in turn, health. 380 
The widespread use of broad-spectrum antibiotics, such as amoxicillin, to treat childhood 381 
infections has been linked to a dramatic decrease in Helicobacter pylori carriage [103]. However, 382 
studies indicate that those who did not acquire H. pylori in childhood were more likely to 383 
subsequently develop asthma, hay fever and skin allergies [104], while other investigations suggest 384 
that H. pylori infection has a protective effect with respect to the development of allergic asthma in 385 
mouse models [105]. The use of some broad-spectrum antibiotics, including clindamycin, ampicillin, 386 
amoxicillin, cephalosporins and flouroquinolones, can also result in Clostridium difficile overgrowth 387 
by impacting the resident gut microbiota, followed by antibiotic-associated diarrhoea, 388 
pseudomembranous colitis and, potentially, life-threatening complications such as toxic megacolon 389 
[106,107]. Low doses of antibiotics have also been used as growth promoters in agriculture since the 390 
1950’s despite an unclear understanding of the mechanisms at work. A recent investigation into this 391 
effect revealed subtherapeutic antibiotic treatment (STAT) of various antibiotics increased adiposity 392 
and hormones related to metabolism in young mice compared to untreated controls [108]. Analysis of 393 
the composition and function of the gut microbiota of these animals made it apparent that STAT 394 
exposure selected for microbial species that were able to extract more calories from dietary complex 395 
carbohydrates that were otherwise indigestible in the control group [108]. 396 
When considering these results, it is important to be aware that different broad-spectrum 397 
antibiotics differ with respect to their impact on the gut microbiota. Changes to the gut microbiota can 398 
also be either long- or short-term. In one instance this was highlighted through murine studies which 399 
established that mice treated with a cocktail of amoxicillin, metronidazole and bismuth [3.0 mg, 0.69 400 
mg and 0.185 mg, respectively] daily for 10 days had largely recovered their baseline microbial 401 
community structure 2 weeks post-treatment but that treatment with cefoperazone [0.5 mg/ml of 402 
drinking water] had long-term effects on community structure and reduced overall diversity [109]. 403 
The effect of an antibiotic on the gut microbiota is influenced by several factors including its 404 
antimicrobial effect (bactericidal or bacteriostatic), its mode of action, the structure of the microbiota 405 
and the distribution of antibiotic resistance genes among this population [110]. 406 
In light of this greater appreciation of the impact of broad spectrum antimicrobials on the gut 407 
microbiota, it is apparent that there is value in utilising antimicrobials with a narrow spectrum of 408 
inhibition. In addition to existing repositories of narrow spectrum antimicrobials that were not 409 
previously commercialised, it is worth noting that the gut microbiota is considered a rich, but yet 410 
relatively, underutilised source of antimicrobial-producing, and in particular bacteriocin-producing, 411 
bacteria. Bacteriocins are ribosomally synthesised peptides to which the producer has a specific 412 
immunity gene and can have either a narrow or broad spectrum of activity [111]. Many bacteriocins 413 
have a number of desirable traits, including low toxicity, high potency and, in the case of gut 414 
associated strains, the possibility of in situ antimicrobial. This combination of traits makes them 415 
attractive alternatives to traditional antibiotic therapies. Despite being, as stated above, a relatively 416 
underutilised source of antimicrobials, a number of bacteriocins have previously been isolated from 417 
mammalian gut microbes [112-115]. Indeed, for example, screening of faecal samples from 266 418 
elderly Irish subjects identified 13 bacteriocin producing strains [115] while a further study lead to the 419 
isolation of 23 distinct bacteriocin-producing strains from a range of mammalian gastrointestinal 420 
sources [112]. Given that, for a bacteriocin to be produced and be active in the gut, the producer needs 421 
to be able to survive in and colonize the human gut and the associated antimicrobial needs to be active 422 
in the gut environment, it has been argued that the gut is an ideal source of bacteriocin producers with 423 
the potential to alter the gut microbiota [116]. There have already been a number of studies which 424 
have highlighted the merits of employing gut-associated bacteriocins, several of which we refer to 425 
here. In a distal colon model, the narrow spectrum bacteriocin thuricin CD has been observed to 426 
inhibit the growth of C. difficile without having any significant additional impact on the other 427 
components of the gut microbiota [113]. This contrasted with the significant shift in the relative 428 
proportions of the dominant bacterial populations that were observed when the broad-spectrum 429 
antimicrobials lacticin 3147, metronidazole and vancomycin, respectively, were employed. Notably, 430 
thuricin CD also exhibited a potency comparable to that of the control antimicrobials [113], thereby 431 
establishing that thuricin CD has potential as an alternative to the conventional antimicrobial 432 
strategies employed to treat C. difficile infection, especially as it is less likely to impact negatively on 433 
the commensal gut microbiota and, thus, is more likely to prevent recurrent C. difficile infections. 434 
While, in the above example, thuricin CD, rather than the associated Bacillus thuringiensis producer 435 
[106], was employed, there are other examples that have highlighted the merits of using the 436 
bacteriocin-producing strain itself. In one such instance, ingestion of the bacteriocin producing 437 
probiotic strain Lactobacillus salivarius UCC118 provided significant protection against infection by 438 
Listeria monocytogenes in mice [117]. Production of the Abp118 bacteriocin by UCC118, which has 439 
previously been shown to be capable of altering the intestinal microbiota of pigs and mice [118], 440 
proved to be the key protective factor as a non-bacteriocin producing mutant failed to confer the same 441 
protection. This protective effect was also lost when infection was with a bacteriocin-immune L. 442 
monocytogenes mutant, thereby confirming that the mode of action was direct antagonism by Abp118 443 
rather than via some other indirect effect [117]. In another instance a combination of 5 probiotic 444 
strains were employed to control Salmonella Typhimurium-induced diarrhoea in pigs [119]. It was 445 
subsequently established that the only bacteriocin-producing strain, L. salivarius DPC6005, was the 446 
dominant member of the cocktail in both the ileum digesta and in the mucosa. It could not be 447 
established, however, if bacteriocin production was directly responsible for anti-Salmonella activity 448 
[120]. 449 
In addition to the control of pathogens, antimicrobials have also been investigated with a view 450 
to altering metabolic health in diet-induced obese mice [121]. Supplementation of a high-fat diet with 451 
vancomycin caused a significant decrease in Firmicutes and Bacteroidetes populations with a 452 
corresponding increase in Proteobacteria. This compositional shift was accompanied by a marked 453 
decrease in weight gain, fasting blood glucose, plasma TNFα and triglyceride levels compared to the 454 
diet-induced obese controls. Although supplementation of the high-fat diet with the bacteriocin-455 
producing probiotic L. salivarius UCC118 did not produce any significant changes in the metabolic 456 
profiles of the mice, it did result in an increase in relative proportions of Bacteroidetes and 457 
Proteobacteria with a corresponding decrease in Actinobacteria. The authors concluded that 458 
antimicrobial strategies have the potential to alter both the composition of the gut microbiota and the 459 
metabolic health of the host. However, it was noted that care must be taken when choosing the 460 
antimicrobial to be used so as to bring about extended beneficial impacts on metabolic health. 461 
As with diet, the vast majority of work concerning modulation of the microbiota by 462 
antimicrobials has taken place in mouse models. Nevertheless, the results are encouraging and suggest 463 
that carefully selected antimicrobials represent a viable option with respect to intelligently altering the 464 
bacterial populations within the human gut. 465 
Modulation by Probiotics 466 
The World Health Organization defines probiotics as “live microorganisms which when administered 467 
in adequate amounts confer a health benefit on the host” [122]. Probiotics are becoming increasingly 468 
popular and are generally marketed as functional foods or dietary supplements. As it has been 469 
recognised that changes in the gut microbiota play a role in GI disease then it is not surprising that 470 
probiotics are an attractive option with respect to modulation of the gut microbiome. For a probiotic to 471 
successfully exert its benefit on the host’s gut microbiota it should be able to remain viable during 472 
storage and also be capable of surviving, and potentially colonizing, the host’s intestinal environment 473 
[123]. The majority of probiotics currently used are members of lactic acid bacteria (LAB) and, more 474 
specifically, strains from the genera Lactobacillus and Bifidobacterium are most commonly used in 475 
commercial probiotics. Mixtures of these strains are becoming increasingly popular as researchers 476 
gain a deeper understanding of increasing efficacy via possible additive or synergistic effects [124]. 477 
Rijkers et al. categorised the benefit of probiotics into three levels based on location and method; 1) 478 
interference with the growth or survival of pathogenic microorganisms in the gut lumen, 2) 479 
improvement of mucosal barrier function or mucosal immune system and 3) influence beyond the gut 480 
through the systemic immune system and other organs [125]. A study undertaken by Park et al. found 481 
that DIO mice treated with the probiotic strains Lactobacillus curvatus HY7601 and Lactobacillus 482 
plantarum KY1032 experienced reduced body weight gain and fat accumulation in addition to 483 
lowered plasma insulin, leptin, total-cholesterol and liver toxicity biomarkers compared to a group on 484 
the same diet supplemented with a placebo [126]. Supplementation with these probiotic strains also 485 
resulted in down-regulation of pro-inflammatory genes in adipose tissue, up-regulation of fatty acid 486 
oxidation-related genes in the liver and significant alterations in the diversity and function of the gut 487 
microbiota. Similar results were observed by Yadav et al., who found that administration of the 488 
probiotic VSL#3 prevented and treated obesity and diabetes in a number of different murine models 489 
through modulation of the gut microbiota. In particular, an increase in the number of butyrate-490 
producing bacteria was linked with enhanced secretion of the hunger-reducing hormone GLP-1 as 491 
well as upregulation of genesinvolved in GLP-1 synthesis and excretion [127]. McNulty et al. 492 
observed that, in gnotobiotic mice harbouring a 15-member model human gut microbial community, 493 
introduction of 5 probiotic strains isolated from a fermented milk product did not significantly alter 494 
the composition of the intestinal microbiota but instead increased the expression of microbial genes 495 
involved in carbohydrate and nucleotide metabolism while decreasing expression of genes involved in 496 
the metabolism of lipids and amino acids [128]. These metatranscriptomic changes were also apparent 497 
in the microbiota of human monozygotic twins when fed the same fermented milk product, primarily 498 
upregulation of genes involved in carbohydrate metabolism. In addition to their investigation with a 499 
view to contributing to the prevention/treatment of obesity and T2D, it should be noted that probiotics 500 
are thought to have the potential to treat a wide range of other conditions such as IBS, allergies, C. 501 
difficile infection, IBD and others by modulation of the gut microbiota as highlighted in a number of 502 
recent manuscripts [129-135]. As we learn more about other gut microbes and their role in human 503 
health it may emerge that the future of probiotics lies in different, non-traditional probiotics, for 504 
example Akkermansia muciniphila as mentioned previously [43].  A recent review by Neef and Sanz 505 
discusses some of the strains already being investigated and the new techniques employed to assess 506 
their impact on human health [136]. 507 
Modulation by Faecal Microbiota Transplantation 508 
Following on from the probiotics principle, but on a community rather than strain level, faecal 509 
microbial transplantation (FMT) is the process of transplanting faecal bacterial communities from a 510 
healthy individual to a recipient whose microbiota has been disrupted or altered. Although still 511 
somewhat in its infancy, FMT is becoming more commonly used as an approach to replenish the gut 512 
microbiota in order to alleviate the symptoms of disease. To date, FMT has most commonly been 513 
used to treat recurrent C. difficile infection (CDI) by replacing populations of commensal bacteria 514 
which have been wiped out by antibiotic therapy. Khoruts and colleagues used terminal-restriction 515 
fragment length polymorphism and 16S rRNA approaches to compare the bacterial component of a 516 
CDI patient’s microbiota before and after FMT intervention [137] and found that, before intervention, 517 
the microbiota was deficient in both Bacteroidetes and Firmicutes but 14 days post-transplantation the 518 
microbiota was changed to closely resemble the donor’s microbiota and was dominated by 519 
Bacteroides spp. [137]. These results are similar to findings by Tvede and Rask-Madsen who reported 520 
Bacteroides spp. were absent in CDI patients but were replenished after FMT intervention [138]. The 521 
composition of the donor’s microbiota is the key factor in determining the efficacy of this treatment, 522 
as shown by Grehan et al. who collected faecal samples from patients undergoing FMT at 4 time 523 
points; pre-treatment and at intervals of 4, 8 and 24 weeks post-treatment to determine the effect of 524 
FMT on its microbial content [138]. Using a molecular approach they found that the microbiota was 525 
altered by FMT intervention and that at 4, 8 and 24 weeks the community of the recipient was 526 
composed predominately of bacteria derived from the healthy donor’s samples. Crucially, in addition 527 
to bringing about desirable microbiota-related changes, FMT has in a high frequency of cases been 528 
successful in controlling CDI. In one such study it was revealed that only 1 of 16 patients treated with 529 
FMT experienced a recurrence of colitis during the 90 day follow-up period [139]. Indeed, when 530 
many such studies were combined in a systematic literature review by Gough et al., i.e. to examine 531 
the effect of FMT on 317 CDI patients across 27 case studies, it was revealed that disease was 532 
resolved in 92% of cases [140]. An interesting development in the application of FMT is the use of 533 
synthetic microbial communities in place of undefined mixtures from donors (for review see de Vos et 534 
al [141]). The synthetic mixtures have the advantage of being controlled, tested extensively for the 535 
presence of viruses or pathogens and have the potential to be reproducibly manufactured. Petrof et al. 536 
showed that a defined mixture of 33 isolates, when administered during a colonoscopy, cured the CDI 537 
of 2 patients who had previously failed to respond to antibiotic treatment [142]. 16S rRNA analysis 538 
showed that the strains found in the stool substitute were rare in the patient’s gut microbiota before 539 
intervention, however following treatment these strains accounted for over 25% of sequences 540 
recovered from the gut microbiota. Although FMT has been most extensively studied with a 541 
view to CDI treatment, it has, however, also been investigated as a potential treatment option for a 542 
range of microbiota-associated diseases including IBD, IBS, obesity, idiopathic thrombocytopaenic 543 
purpura and even multiple sclerosis. A recently published review by Borody et al. summarises the 544 
current state of research and possible future directions of the technique [143].  545 
CONCLUDING REMARKS 546 
It is well established that the gut microbiota influences host metabolism, nutrient absorption 547 
and immune function, and that disruption of this balanced community can have very serious health 548 
implications. As we gain a deeper understanding of the specific relationships between the gut 549 
microbiota and disease, we expose potential therapeutic targets. Intelligent modulation of the 550 
intestinal community is a topic that had gained considerable interest and has the possibility to be 551 
extremely beneficial for human health. 552 
FUNDING 553 
 C.J.W, C.M.G. and P.D.C are supported by a SFI PI award “Obesibiotics” (11/PI/1137) 554 
CONFLICT OF INTEREST STATEMENT 555 
The authors declare no conflicts of interest in preparing this article. 556 
  557 
Table 1. Some examples of studies assessing the influence of diet on the microbiota and health of the 558 
host. 559 
Diet Effect on microbiota Effect on host 
Rich in plant-derived 
polysaccharides [62,96]. 
Increased Bacteroidetes, 
decreased Firmicutes [96]. 
Associated with Prevotella-rich 
enterotype [62]. 
Faster gut transit time 
compared to high protein 
and animal fat diet [62]. 
Omnivorous compared to 
vegetarian and lacto-vegetarian 
[97-99]. 
Increased Clostridium clusters IV 
and XIVa [97-99]. 
Not reported 
High-fat, simple carbohydrate 
“Western” diet [38,40]. 
Increased Firmicutes, decreased 
Bacteroidetes [38,40]. 
Diet-induced obesity. 
Subsequent transplantation 
of obese microbiota to 
germ free mice increased 
adiposity [40]. 
Reduced carbohydrate intake 
[63]. 
Reduced Bifidobacterium, Roseburia 
spp. and Eubacterium rectale [63]. 
Not reported 
Animal product-based [61]. High 
protein and animal fat [62]. 
Increased β-diversity and bile-
tolerant bacteria, including 
Bacteroides, decreased Firmicutes 
[61]. Associated with Bacteroides-
rich enterotype [62]. 
Decreased weight 
independent of calories 
consumed [61]. 
Less fruit, vegetables and fish 
[100]. 
Reduced microbial gene richness 
[100]. 
Increased insulin resistance, 
fasting serum triglyceride 
levels, LDL cholesterol and 
inflammation [100]. 
Reduced variety due to long-stay 
care [60]. 
Increased Bacteroidetes and reduced 
overall diversity [60]. 
Increased frailty and poorer 
general health [60]. 
Changed from a vegetarian diet to 
an animal-based diet [61]. 
Decreased Prevotella, increased 
Bacteroides [61]. 
Not reported 
 560 
  561 
Table 2. Some examples of studies assessing the influence of antimicrobials on the gut microbiota 562 
and, where relevant, the host. 563 
Antimicrobial Effect on Microbiota Physiological effect on host 
Thuricin CD Eliminated C. difficile without impacting 
overall microbiota composition [113]. 
Not examined – distal colon model 
Abp118 Protection against Listeria monocytogenes 
infection [117]. 
Increased Bacteroidetes and Proteobacteria, 
decreased Actinobacteria [120]. 
Temporarily reduced weight gain in pigs 
[117]. 
Vancomycin Decreased Firmicutes and Bacteroidetes, 
increased Proteobacteria [121]. 
Decrease in weight gain, fasting blood 
glucose, plasma TNFα and triglyceride 
levels in DIO mice [121]. 
Sub-
therapeutic 
antibiotic 
therapy* 
Increased Firmicutes, especially 
Lachnospiraceae, relative to Bacteroidetes 
[108]. 
Increased adiposity and bone mineral 
density in mice [108]. 
5 strain 
probiotic 
mixture** 
Reduced shedding of Samonella enterica 
serovar Typhimurium in pigs[119]. 
Reduced incidence, severity and 
duration of diarrhoea in pigs. Also, 
increased weight gain [119]. 
Lactobacillus 
gasseri 
SBT2055, 
producer of 
gassericin T 
bacteriocin 
Not reported Decreased abdominal adiposity, body 
weight, BMI, waist circumference and 
hip circumference in human adults 
[131]. 
Lower triglyceride levels and reduced 
expression of lipogenic and pro-
inflammatory genes in DIO mice [135]. 
* Penicillin, vancomycin, penicillin plus vancomycin, and chlortetracycline 564 
** Lactobacillus murinus DPC6002, Lactobacillus murinus DPC6003, Lactobacillus 565 
pentosus DPC6004, Lactobacillus salivarius DPC6005, and Pediococcus pentosaceus DPC6006 566 
  567 
 568 
Fig. 1. Potential strategies for manipulation of the gut microbiota. 569 
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